Fluorescent microscopy image of the new cells (extraembryonic mesoderm cells) and placenta progenitor stem cells. The new cells are marked in red, and cells corresponding to placental stem cells are shown in green. The DNA (nucleus) of each cell is shown in blue.
© Amitesh Panda (KU Leuven)

Researchers from KU Leuven for the first time have produced human cells able to mimic the molecular mechanisms of early human embryogenesis and related defects.

© Charité | Anja Hagemann

A small prospective study among mid-aged people has demonstrated that a mild SARS-CoV-2 infection triggers ME/CF in 50% of the study population.<button lang="en-GB" aria-description="Klicken, um Alternative zu verwenden">
</button>

© Bactolife A/S

Swedish food and feed supplement specialist Bactolife A/S has received US$5m in funding from the Bill & Melinda Gates Foundation to address gastrointestinal infections.

© Pixabay.com

For the second time within a short period of time, a competitor has sued the mRNA vaccine developer BioNtechPfizer for patent infringement.

LNP ©NCI/Adapted from Vaccines. January 2021. https://doi.org/10.3390/vaccines9010065. CC BY 4.0.

Moderna co-founder Kenneth Chien and Novalis LifeSciences LLC are the lead investors of a €39m Series B2 financing in eTheRNA.

A fundus photo showing intermediate age-related macular degeneration. © National Eye Institute, National Institutes of Health

Kinarus Therapeutics Holding AG has raised US$20m in financing through the issuance of convertible bonds to YA II PN, Ltd.

Pixabay.com

A study in the scientific journal The Lancet shows that half of all global cancer deaths are due to life style-related risk factors such as smoking and alcohol use.

Ryvu Therapeutics' R&D centre at Krakow. © Ryvu Therapeutics

Polish cancer drug developer, Ryvu Therapeutics, has received €22m funding from the European Investment Bank via its venture debt instrument.

©Avantium NV

Avantium and AmBev, part of AB InBev Group, have inked an agreement on PEF for soft drink bottles.

SHREAD-transduced cells (blue), expressed trastuzumab (yellow), and tumour vasculature (red). © PNAS, 10.1073/pnas.201792511

With a Series A funding of CHF 30m from Versant Ventures, Vector Biopharma AG set out to solve several of the current gene delivery problems.